AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2569959 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg/day)
Number of subjects: 40
Study 2569959 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol (20 mg/day)
Number of subjects: 40
Study 2569959 — intervention group
Group type: EXPERIMENTAL
Intervention: Minoxidil (5.5 mg/day, added at week 6 if SDAP > 95 mm Hg)
Number of subjects: 40
Study 30256919 — intervention group
Group type: EXPERIMENTAL
Intervention: Unstimulated plasma analytes
Number of subjects: 421
Study 30256919 — intervention group
Group type: COMPARATOR
Intervention: Predictive model analysis using unstimulated analytes
Number of subjects: 421
Study 30256919 — intervention group
Group type: EXPERIMENTAL
Intervention: Unstimulated IL-2 and IFN-γ
Number of subjects: 421
Study 30256919 — intervention group
Group type: EXPERIMENTAL
Intervention: Background-adjusted values
Number of subjects: 421
Study 27894198 — intervention group
Group type: EXPERIMENTAL
Intervention: 27 mg elemental iron daily (group I)
Number of subjects: 120
Study 27894198 — intervention group
Group type: EXPERIMENTAL
Intervention: 54 mg elemental iron daily (group II)
Number of subjects: 120
Study 25301007 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care interventions developed by the clinical pharmacist in collaboration with the physician
Number of subjects: 106
Study 25301007 — intervention group
Group type: COMPARATOR
Intervention: Usual care without clinical pharmacist's input
Number of subjects: 106
Study 25301007 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care interventions
Number of subjects: 106
Study 24189342 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine, 40 mg per day for 3 weeks
Number of subjects: 35
Study 24189342 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 22963463 — intervention group
Group type: EXPERIMENTAL
Intervention: Below knee stockinette application
Number of subjects: 0
Study 22963463 — intervention group
Group type: EXPERIMENTAL
Intervention: Above knee stockinette application
Number of subjects: 0
Study 19297430 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet (30.8% of energy)
Number of subjects: 0
Study 19297430 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-fat, high polyunsaturated fat diet (36.3% of energy)
Number of subjects: 0
Study 19297430 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate in fat and saturated fat diet (37.9% of energy, 11.4% of energy respectively)
Number of subjects: 0
Study 19297430 — intervention group
Group type: COMPARATOR
Intervention: Control group not explicitly mentioned
Number of subjects: 0
Study 17537204 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular pacing (BiV)
Number of subjects: 200
Study 17537204 — intervention group
Group type: COMPARATOR
Intervention: Conventional right ventricular apical (RVA) pacing
Number of subjects: 200
Study 15468944 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine concentration of 370 mg/mL (Group B)
Number of subjects: 100
Study 15468944 — intervention group
Group type: COMPARATOR
Intervention: Iodine concentration of 300 mg/mL (Group A)
Number of subjects: 100
Study 11161898 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-acquired yeast carriage
Number of subjects: 69
Study 11161898 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-acquired yeasts
Number of subjects: 69
Study 11161898 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare workers colonization
Number of subjects: 69
Study 11161898 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-to-person transmission
Number of subjects: 69
Study 9630813 — intervention group
Group type: EXPERIMENTAL
Intervention: Salofalk (500 mg)
Number of subjects: 12
Study 9630813 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentasa (500 mg)
Number of subjects: 12
Study 8310405 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis (1 gm cephalothin intravenously 30 minutes before the procedure and 500 mg cephalexin orally every 6 hours for 3 days afterward)
Number of subjects: 84
Study 8310405 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antibiotics)
Number of subjects: 84
Study 2646421 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing (S&RP) with open flap procedure
Number of subjects: 114
Study 2646421 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (S&RP) alone
Number of subjects: 114
Study 2646421 — intervention group
Group type: EXPERIMENTAL
Intervention: More experienced operators
Number of subjects: 114
Study 2646421 — intervention group
Group type: COMPARATOR
Intervention: Less experienced operators
Number of subjects: 114
Study 4930389 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulphan
Number of subjects: 726
Study 4930389 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Number of subjects: 726
Study 4930389 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 726
Study 30691442 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic adjustable gastric banding combined with lifestyle interventions
Number of subjects: 60
Study 30691442 — intervention group
Group type: COMPARATOR
Intervention: Combined lifestyle interventions
Number of subjects: 60
Study 26956782 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics-supplemented group
Number of subjects: 60
Study 25790882 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 322
Study 23564395 — intervention group
Group type: EXPERIMENTAL
Intervention: Ending the discussion with a question (autonomy approach)
Number of subjects: 78
Study 23564395 — intervention group
Group type: COMPARATOR
Intervention: Ending the discussion with a recommendation (beneficence approach)
Number of subjects: 78
Study 23564395 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who had chosen DNR for themselves
Number of subjects: 78
Study 23564395 — intervention group
Group type: COMPARATOR
Intervention: Patients who had not chosen DNR for themselves
Number of subjects: 78
Study 21703048 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil plus Vacuum Erection Device (VED), 10 minutes unbanded per day for at least 5 days weekly
Number of subjects: 23
Study 21703048 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil plus Vacuum Erection Device (VED)
Number of subjects: 23
Study 21703048 — intervention group
Group type: COMPARATOR
Intervention: Tadalafil
Number of subjects: 23
Study 17565213 — intervention group
Group type: EXPERIMENTAL
Intervention: Group reminiscence approach (GRA)
Number of subjects: 60
Study 17565213 — intervention group
Group type: EXPERIMENTAL
Intervention: Social contact
Number of subjects: 60
Study 17565213 — intervention group
Group type: COMPARATOR
Intervention: Control (supportive care)
Number of subjects: 60
Study 16093403 — intervention group
Group type: EXPERIMENTAL
Intervention: Powdered fermented milk with L. helveticus CM4 (12 g daily for 4 weeks)
Number of subjects: 80
Study 16093403 — intervention group
Group type: COMPARATOR
Intervention: Placebo (12 g daily for 4 weeks)
Number of subjects: 80
Study 12174393 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic aspiration hepatectomy (group T)
Number of subjects: 315
Study 12174393 — intervention group
Group type: COMPARATOR
Intervention: Conventional hepatectomy (group C)
Number of subjects: 315
Study 10442275 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide at a dose of 2,400 micrograms daily
Number of subjects: 9
Study 10442275 — intervention group
Group type: COMPARATOR
Intervention: Systemic corticosteroid (standard adjunctive therapy)
Number of subjects: 9
Study 7792016 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperuricemia group (148 subjects with ischemic heart disease)
Number of subjects: 370
Study 7792016 — intervention group
Group type: COMPARATOR
Intervention: Control group (222 subjects without ischemic heart disease)
Number of subjects: 370
Study 7792016 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperuricemia group with triglycerides > 200 mg/dl
Number of subjects: 370
Study 7792016 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole group and males
Number of subjects: 370
Study 7792016 — intervention group
Group type: EXPERIMENTAL
Intervention: Females aged 60-69 years vs 70-79 years
Number of subjects: 370
Study 2217030 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam 4 mg twice daily
Number of subjects: 45
Study 2217030 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 50 mg twice daily
Number of subjects: 45
Study 2217030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 883330 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple mastectomy with pectoral lymph node biopsy
Number of subjects: 243
Study 883330 — intervention group
Group type: COMPARATOR
Intervention: Radical mastectomy plus radical radiotherapy
Number of subjects: 243
Study 883330 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple mastectomy
Number of subjects: 243
Study 30413151 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab 120 mg
Number of subjects: 270
Study 30413151 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab 240 mg
Number of subjects: 270
Study 30413151 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab 120 mg and 240 mg
Number of subjects: 270
Study 26487585 — intervention group
Group type: EXPERIMENTAL
Intervention: IHC (Immunohistochemistry)
Number of subjects: 436
Study 26487585 — intervention group
Group type: EXPERIMENTAL
Intervention: IHC (Immunohistochemistry) with iScore 3
Number of subjects: 436
Study 26487585 — intervention group
Group type: EXPERIMENTAL
Intervention: IHC-positive patients with atypical FISH pattern
Number of subjects: 436
Study 26487585 — intervention group
Group type: COMPARATOR
Intervention: IHC staining intensity
Number of subjects: 436
Study 24434887 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration training (9 mins per day, 5 days per week)
Number of subjects: 30
Study 24434887 — intervention group
Group type: COMPARATOR
Intervention: Traditional physical therapy exercise program (3 months)
Number of subjects: 30
Study 22547995 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin
Number of subjects: 212
Study 20933640 — intervention group
Group type: EXPERIMENTAL
Intervention: Helical multidetector CT (MDCT)
Number of subjects: 0
Study 20933640 — intervention group
Group type: COMPARATOR
Intervention: Sequential multidetector CT (MDCT)
Number of subjects: 0
Study 18655983 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsular bending ring (CBR) implantation
Number of subjects: 60
Study 18655983 — intervention group
Group type: COMPARATOR
Intervention: Intraocular lens (IOL) implantation alone (no CBR)
Number of subjects: 60
Study 15878726 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual warning signal with random foreperiod (1.0‐6.5 s)
Number of subjects: 0
Study 12648204 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine
Number of subjects: 40
Study 12648204 — intervention group
Group type: COMPARATOR
Intervention: 0.2% ropivacaine
Number of subjects: 40
Study 11117682 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid fixation
Number of subjects: 126
Study 11117682 — intervention group
Group type: COMPARATOR
Intervention: Wire fixation
Number of subjects: 126
Study 8959628 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-8
Number of subjects: 5
Study 8959628 — intervention group
Group type: EXPERIMENTAL
Intervention: huGRO alpha
Number of subjects: 5
Study 8959628 — intervention group
Group type: EXPERIMENTAL
Intervention: MCP-1
Number of subjects: 5
Study 8959628 — intervention group
Group type: EXPERIMENTAL
Intervention: RANTES
Number of subjects: 5
Study 1541613 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 800-centigray dose of limited-field radiation
Number of subjects: 55
Study 1541613 — intervention group
Group type: COMPARATOR
Intervention: 1000 centigray of limited-field radiation in divided doses
Number of subjects: 55
Study 1541613 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 55
Study 3993426 — intervention group
Group type: EXPERIMENTAL
Intervention: Iohexol 350 mg I/ml, 500 mg I/kg body weight
Number of subjects: 20
Study 3993426 — intervention group
Group type: COMPARATOR
Intervention: Metrizoate 350 mg I/ml, 500 mg I/kg body weight
Number of subjects: 20
Study 3993426 — intervention group
Group type: EXPERIMENTAL
Intervention: Iohexol and Metrizoate
Number of subjects: 20
Study 29935583 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1.5 ng ml‐1)
Number of subjects: 160
Study 29935583 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (1.7 μg ml‐1)
Number of subjects: 160
Study 29935583 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (0.9% end‐tidal)
Number of subjects: 160
Study 29935583 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ketamine (0.75 μg ml‐1)
Number of subjects: 160
Study 29935583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 27142970 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular TXA (IA group)
Number of subjects: 75
Study 27142970 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous TXA (IV group)
Number of subjects: 75
Study 27142970 — intervention group
Group type: COMPARATOR
Intervention: No TXA (Control group C)
Number of subjects: 75
Study 24262818 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT) plus usual care
Number of subjects: 0
Study 24262818 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 0
Study 21917054 — intervention group
Group type: EXPERIMENTAL
Intervention: AA attendance
Number of subjects: 1726
Study 20189555 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted hatching (AH) performed near the inner cell mass (ICM)
Number of subjects: 0
Study 20189555 — intervention group
Group type: COMPARATOR
Intervention: Assisted hatching (AH) at the side opposite to the ICM
Number of subjects: 0
Study 18062586 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium treatment
Number of subjects: 137
Study 18062586 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocalcaemia during treatment
Number of subjects: 137
Study 15714933 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 Gy in 10 fractions (regimen 2)
Number of subjects: 149
Study 15714933 — intervention group
Group type: COMPARATOR
Intervention: 10 Gy single fraction (regimen 1)
Number of subjects: 149
Study 11834357 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 86
Study 11834357 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 86
Study 10574605 — intervention group
Group type: EXPERIMENTAL
Intervention: S100
Number of subjects: 43
Study 10574605 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB45
Number of subjects: 43
Study 10574605 — intervention group
Group type: EXPERIMENTAL
Intervention: NKI
Number of subjects: 43
Study 10574605 — intervention group
Group type: EXPERIMENTAL
Intervention: AAT
Number of subjects: 43
Study 10574605 — intervention group
Group type: EXPERIMENTAL
Intervention: CD68
Number of subjects: 43
Study 10574605 — intervention group
Group type: EXPERIMENTAL
Intervention: HAM56
Number of subjects: 43
Study 10574605 — intervention group
Group type: EXPERIMENTAL
Intervention: Mac387
Number of subjects: 43
Study 10574605 — intervention group
Group type: EXPERIMENTAL
Intervention: Muramidase
Number of subjects: 43
Study 8918628 — intervention group
Group type: EXPERIMENTAL
Intervention: Epo (150 U/kg.week s.c.)
Number of subjects: 29
Study 8918628 — intervention group
Group type: COMPARATOR
Intervention: Non-Epo treatment
Number of subjects: 29
Study 8918628 — intervention group
Group type: EXPERIMENTAL
Intervention: Epo treatment
Number of subjects: 29
Study 1323587 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-571 (450 mg total dose)
Number of subjects: 0
Study 1323587 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-571 (37.5 mg total dose)
Number of subjects: 0
Study 1323587 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6381167 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 1600 mg daily
Number of subjects: 50
Study 6381167 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac 100 mg daily
Number of subjects: 50
Study 30738912 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance feedback
Number of subjects: 4
Study 30738912 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal setting
Number of subjects: 4
Study 30738912 — intervention group
Group type: EXPERIMENTAL
Intervention: Both goal setting and performance feedback
Number of subjects: 4
Study 30738912 — intervention group
Group type: COMPARATOR
Intervention: None (control)
Number of subjects: 4
Study 29705803 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering pretreatment
Number of subjects: 3284
Study 29705803 — intervention group
Group type: COMPARATOR
Intervention: Low-dose alteplase (0.6 mg/kg)
Number of subjects: 3284
Study 29705803 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose alteplase (0.9 mg/kg)
Number of subjects: 3284
Study 28965385 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Jujing No.2 Decoction (1 dose a day, bid)
Number of subjects: 70
Study 28965385 — intervention group
Group type: COMPARATOR
Intervention: Danshen Tablets (4 tablets once, tid) plus Liu Wei Di Huang Wan (8 pills once, tid)
Number of subjects: 70
Study 23869061 — intervention group
Group type: EXPERIMENTAL
Intervention: Sapropterin (10 mg/kg)
Number of subjects: 10
Study 23869061 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 21816634 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum assist technique for glenoid fixation
Number of subjects: 96
Study 21816634 — intervention group
Group type: COMPARATOR
Intervention: Control group using modern 'third generation' cementing techniques
Number of subjects: 96
Study 21816634 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 96
Study 19536889 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined androgen blockade (CAB) with LHRH-A plus bicalutamide 80 mg
Number of subjects: 205
Study 19536889 — intervention group
Group type: COMPARATOR
Intervention: LHRH-A monotherapy
Number of subjects: 205
Study 16690640 — intervention group
Group type: EXPERIMENTAL
Intervention: High Frequency Oscillatory Ventilation (HFOV)
Number of subjects: 585
Study 16690640 — intervention group
Group type: COMPARATOR
Intervention: Conventional Ventilation (CV)
Number of subjects: 585
Study 14726728 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 19
Study 14726728 — intervention group
Group type: COMPARATOR
Intervention: Pimozide
Number of subjects: 19
Study 11770031 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid (250 mg of prednisolone)
Number of subjects: 160
Study 11770031 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (6 Mio. KIU)
Number of subjects: 160
Study 11770031 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin coating of the artificial surface (Bioline)
Number of subjects: 160
Study 11770031 — intervention group
Group type: COMPARATOR
Intervention: Standard medication (control group)
Number of subjects: 160
Study 9051894 — intervention group
Group type: EXPERIMENTAL
Intervention: 360 degrees lumbar fusion with decompression
Number of subjects: 81
Study 9051894 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgery (control group)
Number of subjects: 81
Study 7506452 — intervention group
Group type: EXPERIMENTAL
Intervention: FK506
Number of subjects: 31
Study 7506452 — intervention group
Group type: COMPARATOR
Intervention: CsA
Number of subjects: 31
Study 2829953 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (400, 600, 800 micrograms)
Number of subjects: 6
Study 2829953 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (400, 600, 800 micrograms)
Number of subjects: 6
Study 2829953 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs (Fenoterol and Salbutamol)
Number of subjects: 6
Study 29566816 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-On
Number of subjects: 807
Study 29566816 — intervention group
Group type: COMPARATOR
Intervention: CRT-Off
Number of subjects: 807
Study 26887029 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical consultation requested prior to PCI (n < 201)
Number of subjects: 427
Study 26887029 — intervention group
Group type: COMPARATOR
Intervention: No surgical consultation requested prior to PCI (n < 226)
Number of subjects: 427
Study 25036533 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg/day
Number of subjects: 21
Study 25036533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 23085705 — intervention group
Group type: EXPERIMENTAL
Intervention: Light support (S1)
Number of subjects: 20
Study 23085705 — intervention group
Group type: EXPERIMENTAL
Intervention: High support (S4)
Number of subjects: 20
Study 23085705 — intervention group
Group type: COMPARATOR
Intervention: No electrical support (NO)
Number of subjects: 20
Study 20022836 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype notification group (intervention group)
Number of subjects: 562
Study 20022836 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 562
Study 18662961 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist Ratio (WR) > or = 0.70
Number of subjects: 67
Study 18662961 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist Palm Ratio > 0.342
Number of subjects: 67
Study 18373122 — intervention group
Group type: EXPERIMENTAL
Intervention: Effortful saliva swallowing
Number of subjects: 27
Study 18373122 — intervention group
Group type: COMPARATOR
Intervention: Noneffortful saliva swallowing
Number of subjects: 27
Study 18373122 — intervention group
Group type: COMPARATOR
Intervention: Control task (repetitive apposition of the dominant thumb and index finger)
Number of subjects: 27
Study 16389981 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced MDCT
Number of subjects: 68
Study 12472583 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg of micronized 17beta‐oestradiol (E2)
Number of subjects: 60
Study 12472583 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg of micronized 17beta‐oestradiol + 10 mg dydrogesterone (E2 + D)
Number of subjects: 60
Study 12472583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 9506490 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone diacetate, 40 mg intramuscular (i.m.)
Number of subjects: 154
Study 9506490 — intervention group
Group type: COMPARATOR
Intervention: Prednisone, 40 mg/day orally for 5 days
Number of subjects: 154